

# Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study

Jenny H.C. Chen<sup>1,2</sup>, Mark A. Brown<sup>3,4</sup>, Matthew Jose<sup>5,6</sup>, Frank Brennan<sup>3,4</sup>, David W. Johnson<sup>7,8,9,10</sup>, Matthew A. Roberts<sup>11,12</sup>, Germaine Wong<sup>13,14,15</sup>, Hicham Cheikh Hassan<sup>1,2</sup>, Alice Kennard<sup>16,17</sup>, Rachael Walker<sup>13,18</sup>, Christopher E. Davies<sup>19,20</sup>, Neil Boudville<sup>21,22</sup>, Monique Borlace<sup>23</sup>, Carmel Hawley<sup>7,8,9,10</sup> and Wai H. Lim<sup>21,22</sup>

<sup>1</sup>School of Medicine, University of Wollongong, Wollongong, Australia, <sup>2</sup>Depatment of Renal Medicine, Wollongong Hospital, Wollongong, Australia, <sup>3</sup>Department of Nephrology, St George Hospital, Sydney, Australia, <sup>4</sup>School of Medicine, University of New South Wales, Sydney, Australia, <sup>5</sup>School of Medicine, The University of Tasmania, Hobart, Australia, <sup>6</sup>Department of Nephrology, Royal Hobart Hospital, Hobart, Australia, <sup>7</sup>Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia, <sup>8</sup>Centre for Health Services Research, University of Queensland, Brisbane, Australia, <sup>9</sup>Translational Research Institute, Brisbane, Australia, <sup>10</sup>Australasian Kidney Trials Network, Brisbane, Australia, <sup>11</sup>School of Medicine, Monash University, Melbourne, Australia, <sup>12</sup>Renal Service, Eastern Health, Melbourne, Australia, <sup>13</sup>Sydney School of Public Health, University of Sydney, Sydney, Australia, <sup>14</sup>Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Australia, <sup>15</sup>Centre for Transplant and Renal Research, Westmead Hospital, Canberra, Australia, <sup>18</sup>School of Nursing, Eastern Institute of Technology, Napier, New Zealand, <sup>19</sup>Australia and New Zealand Dialysis and Transplant Registry, South Australian Health and Medical Research Institute, Adelaide, Australia, <sup>20</sup>Adelaide Medical School, University of Adelaide, Australia, <sup>21</sup>Medical School, University of Western Australia, Perth, Australia, <sup>22</sup>Department of Renal Medicine, Sir Charles Gairdner Hospital, Perth, Australia and <sup>23</sup>Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia

Correspondence to: Jenny H.C. Chen; E-mail: jennyhengchen.chen@health.nsw.gov.au

# ABSTRACT

**Background.** Mortality risk is high soon after dialysis initiation in patients with kidney failure, and dialysis withdrawal is a major cause of early mortality, attributed to psychosocial or medical reasons. The temporal trends and risk factors associated with cause-specific early dialysis withdrawal within 12 months of dialysis initiation remain uncertain.

**Methods.** Using data from the Australia and New Zealand Dialysis and Transplant Registry, we examined the temporal trends and risk factors associated with mortality attributed to early psychosocial and medical withdrawals in incident adult dialysis patients in Australia between 2005 and 2018 using adjusted competing risk analyses.

**Results.** Of 32 274 incident dialysis patients, 3390 (11%) experienced death within 12 months post-dialysis initiation. Of these, 1225 (36%) were attributed to dialysis withdrawal, with 484 (14%) psychosocial withdrawals and 741 (22%) medical withdrawals. These patterns remained unchanged over the past two decades. Factors associated with increased risk of death from early psychosocial and medical withdrawals were older age, dialysis via central venous catheter, late referral and the presence of cerebrovascular disease; obesity and Asian ethnicity were associated with decreased risk. Risk factors associated with early psychosocial withdrawals were underweight and higher socioeconomic status. Presence of peripheral vascular disease, chronic lung disease and cancers were associated with early medical withdrawals.

**Conclusions.** Death from dialysis withdrawal accounted for >30% of early deaths in kidney failure patients initiated on dialysis and remained unchanged over the past two decades. Several shared risk factors were observed between mortality attributed to early psychosocial and medical withdrawals.

**Keywords:** dialysis, frailty, kidney supportive care, mortality, treatment withdrawal

### INTRODUCTION

Withdrawal from kidney replacement therapy is a major cause of death in patients on dialysis. In Australia and New Zealand, the proportion of deaths in incident dialysis patients attributed to dialysis withdrawal increased by 2-fold between 1997 (15%) and 2017 (30%) [1–3]. A similar trend has been observed in the USA, Canada and the UK [4–7]. The reason for the upward

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial reuse, please contact journals.permissions@oup.com

<sup>©</sup> The Author(s) 2021. Published by Oxford University Press on behalf of the ERA-EDTA.

#### What is already known about this subject?

- dialysis withdrawal is a major cause of death in patients with kidney failure, and international registry reports suggested temporal increase in withdrawal-related mortality; and
- risk factors associated with mortality from dialysis withdrawal were older age, Caucasian ethnicity, late nephrologist referral and haemodialysis as initial dialysis modality.

#### What this study adds?

- the proportion of early mortality from dialysis withdrawal has remained unchanged in Australia since 2005;
- the annual proportion of early mortality attributed to medical withdrawals consistently surpassed the proportion of psychosocial withdrawals; and
- early mortality attributed to psychosocial and medical withdrawals was associated with similar risk factors.

#### What impact this may have on practice or policy?

• recognizing the patient at risk of early mortality attributed to dialysis withdrawal may better inform the shared decision-making process, empower patient-focused treatment choices and facilitate advanced care planning.

trend is likely multifactorial including patient selection for dialysis initiation, cultural acceptance of dialysis withdrawal and accessibility of kidney supportive care [3, 8, 9].

Early mortality after dialysis initiation is known to be high [10–12]. A recent US Renal Data System (USRDS) registry study suggested that the risk factors associated with death from dialysis withdrawal were similar to other causes of death within 6-month post-initiation of haemodialysis (HD) [13]. Risk factors associated with death from cause-specific withdrawals have not been studied previously. A greater understanding of these risk factors will better inform shared decision-making, assist appropriate patient selection for dialysis initiation and facilitate institution of pertinent resources allocation.

The aims of this study were 2-fold. First, we examined the temporal trends of death attributed to dialysis withdrawal related to psychosocial and medical reasons in the first 12 months post-dialysis initiation. Secondly, we assessed the risk factors associated with death attributed to early dialysis withdrawal related to psychosocial and medical causes.

# MATERIALS AND METHODS

#### Study cohort

Incident adult patients (aged  $\geq$ 18 years) commencing maintenance dialysis for kidney failure in Australia between 2005 and 2018 were included using data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry, censored on 31 December 2018. The study period was restricted to 2005–18 because ANZDATA expanded the pre-specified withdrawal-related causes of death in October 2003 [14], which was associated with a step-wise increase in deaths from withdrawal between 2004 and 2005. Patients who had commenced dialysis following failure of pre-emptive kidney transplant were also included. Patients who had recovered kidney function or had



**FIGURE 1:** Patient flowchart for adult incident dialysis patients in Australia between 2005 and 2018.

received a kidney transplant within 12 months after dialysis initiation were excluded (Figure 1). The conduct of this study was approved by the University of Western Australia Human Research Ethics Committee, Perth, Australia. The study was conducted in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [15].

#### Data collection

Patient and treatment characteristics at time of dialysis initiation were extracted from the ANZDATA registry, including age, sex, ethnicity, body mass index (BMI), geographical location (urban, regional and remote), socioeconomic status (SES; measured by Index of Relative Socio-economic Advantage and Disadvantage using postcode and categorized into tertiles) [16], era (categorized as 2005-09, 2010-13 and 2014-18), initial dialvsis modality, dialysis access [native arteriovenous fistula (AVF), central venous catheter (CVC), synthetic graft, peritoneal dialysis (PD) catheter], smoking status, comorbid medical conditions (presence or absence of chronic lung disease, coronary artery disease, peripheral vascular disease, cerebrovascular disease, diabetes mellitus and prior cancer), late nephrologist referral (defined as <3 months before dialysis initiation), primary cause of kidney failure (diabetic nephropathy, glomerulonephritis, hypertensive nephrosclerosis, cystic kidney disease and other), state/territory at dialysis initiation and prior preemptive kidney transplantation. Dialysis modality was categorized as HD (both facility HD and home HD) and PD (both continuous ambulatory PD and automated PD). The categorization of the causes of kidney failure was reported to the ANZDATA registry by each treating centre and not verified by the registry. Baseline centre-level characteristics included centre size (calculated as the mean annual number of patients on incident HD, PD or either dialysis modality) and transplant centre. Centre size was divided into quartiles by patient number and grouped into three categories by combining the second and third quartiles. The dialysis centre was defined as the centre where dialysis was initiated, but did not consider the potential transfer to alternative dialysis centre(s) over time.

### **Clinical outcomes**

The primary outcome was death from dialysis withdrawal attributed to psychosocial or medical reasons, separately, within 12 months after dialysis initiation. Death from dialysis withdrawal for psychosocial reasons included psychosocial withdrawal and treatment refusal. Death from dialysis withdrawal from medical reasons included comorbid medical conditions (cardiovascular disease, cerebrovascular disease, peripheral vascular disease or cancer), access difficulties or other reasons. The causes of death were pre-specified in the ANZDATA registry survey form [17].

#### Statistical analysis

The baseline data were expressed as numbers (proportion) for categorical data, mean [standard deviation (SD)] for normally distributed continuous data and median and interquartile range (IQR) for non-normally distributed continuous data. The annual trends of cause-specific early mortality and cause-specific early withdrawal-related mortality were examined and expressed as proportion of total early mortality and annual incidence rates. Time trends of the incidence rates were examined using Joinpoint regression [18]. Mann–Kendall test was used to assess the significance of temporal variations. The association between covariates and early deaths attributed to psychosocial or medical withdrawals was examined using adjusted Cox proportional hazard regressions followed by competing risk regression analyses using the method described by Fine and Gray [19], expressed as subdistribution hazard ratios (SHRs). Covariates included in the competing risk models were identical to those included in the Cox regression models. The starting time in all models was time of dialysis initiation. The proportional hazard assumptions of all models were checked graphically by plotting the Schoenfeld residuals. Collinearity between covariates was checked by correlation matrix of coefficients. Initial dialysis modality was not included in the models because of collinearity with initial dialysis access. For all models, causes of death other than the outcome were considered as competing events. Kidney transplantation was not considered as a competing event as patients who received kidney transplantation within 12 months after dialysis initiation were excluded. The centre-level risk factors associated with early mortality were examined using adjusted  $\gamma$ -distributed Cox shared frailty model, considering initial dialysis centre as the cluster. Covariates with P < 0.1 in the univariate models were included in the multivariable-adjusted models.

Sensitivity analysis restricted to incident patients on dialysis for  $\geq$ 90 days was conducted because of potential ascertainment bias from underreporting of patients on dialysis for <90 days. Statistical evaluation was performed using SPSS version 27, STATA version IC 15.1 and Joinpoint version 4.8.0.1 statistical programmes. P-values <0.05 were considered statistically significant.

## RESULTS

The study cohort comprised 32 274 incident patients who commenced dialysis between 2005 and 2018 in Australia, with 199 (0.6%) having commenced dialysis following pre-emptive kidney transplant failure. The overall follow-up period was 29 046 person-years. Among all incident patients, 3390 (11%) patients experienced early death within 12 months post-dialysis initiation. Of those, 484 (14%) died from early withdrawal for psychosocial reasons, and 741 (22%) for medical reasons (Figure 1). The mean  $\pm$  SD age at dialysis initiation was  $61.9 \pm 14.8$  years. Patients who experienced early withdrawal were more likely to be Caucasian and to have commenced HD as the initial dialysis modality, compared with patients who were alive at 12 months post-dialysis initiation (85% versus 66%, P < 0.001; 87% versus 74%, P < 0.001, respectively). The 32 274 incident patients received dialysis in 97 centres. Table 1 shows the baseline patient and centre characteristics of the study cohort.

#### Temporal trend in the causes of early mortality

The proportion of death from early withdrawal remained unchanged between 2005 and 2017 and accounted for 33–38% of all-cause early mortality. The annual proportions of early psychosocial and medical withdrawals also remained unchanged with the proportion of medical withdrawals consistently surpassing psychosocial withdrawals (Figure 2A). Linear trends were observed in Joinpoint regression for incidence rates of death from early withdrawal. The incidence rates of early

#### Table 1. Baseline characteristics of adult incident dialysis patients in Australia between 1998 and 2018

patient    444    711    72.05    72.24      Age strating dalpsis (man ± SD), years    71.1 ± 1.25    70.9 ± 11.2    67.22 ± 1.33    60.19 ± 1.48      Age, n (%)           Caucasians    400 (64)    60.6 (60)    12.64 (7.0)    30.90 (62)      Asians    17.64    22.03    13.31 (6)    30.94 (10)      Others    32.65    37.65    170.18    30.96 (11)      BMI (mean ± SD), kym²    26.75 ± 6.7    26.8 ± 6.10    27.5 ± 7.0    28.5 ± 7.1      BMI (mean ± SD), kym²    27.66    30.61 (11)    29.00 (11)    100.01 (32)    20.60 (11)      Date requires, n (%)      100.01 (32)    20.60 (11)    20.60		Early death from psychosocial withdrawal	Early death from medical withdrawal	Early death from non-withdrawal causes	Overall
Number of patients    444    741    216    31274      Age starting displicements    235 (59)    431 (61)    1367 (63)    20100 (62)      Caucasians    406 (84)    636 (86)    1634 (76)    21752 (67)      Caucasians    170 (4)    22 (3)    133 (6)    398 (40)      Indigenous'    22 (5)    37 (5)    170 (8)    398 (40)      BMI categories    22 (5)    37 (5)    170 (8)    398 (40)      BMI categories (18)    22 (5)    37 (3)    1008 (35)    895 (3)      Normal    172 (28)    226 (44)    738 (37)    970 (23)      Overweight    168 (33)    219 (31)    619 (38)    1008 (35)      Normal    172 (28)    226 (25)    173 (23)    279 (28)    1080 (35)      Object    163 (23)    219 (31)    619 (32)    2108 (35)    208 (37)      Object    130 (14)    92 (12)    381 (18)    484 (45)    456 (45)      Object    20 (13)    20 (14)    22 (12)    381 (18)    484 (45)	Patient-level characteristics				
Age starting dialpsis (men = SD), years    71, 1 = 1, 2    70.9 ± 11, 2    67.2 ± 13.3    60.1 ± 27.4 ± 13.5      Ethnisiry, n (%)	Number of patients	484	741	2165	32 274
Men, n (%)    285 (sp)    451 (61)    1367 (s)    2001 (62)      Educity, n (%)    -	Age starting dialysis (mean $\pm$ SD), years	$71.1 \pm 12.5$	$70.9\pm11.2$	$67.2 \pm 13.3$	$61.9\pm14.8$
Ethnicity, n (%)    U      Caucasians    406 (84)    636 (66)    1634 (76)    21752 (67)      Asians    17 (4)    22 (3)    133 (6)    3084 (10)      Indigencos*    39 (8)    46 (6)    228 (11)    3834 (12)      BMI (near ±50), kg/m²    26.7 ± 5.7    26.8 ± 7.1    27.8 ± 7.0    28.8 ± 7.1      BMI (near ±50), kg/m²    26.7 ± 5.7    26.8 ± 7.1    27.8 ± 7.0    28.8 ± 7.1      BMI (near ±50), kg/m²    27.6 (10)    30 (4)    100 (5)    895 (3)      Overweight    144 (33)    219 (31)    619 (30)    1006 (13)      Overweight    69 (14)    9.2 (12)    81 (18)    820 (25)      HD    49 (158)    669 (86)    17.64 (82)    24064 (75)      HD    49 (14)    82 (12)    781 (13)    420 (25)      HD    49 (14)    82 (12)    781 (13)    436 (13)      Dalayis acces, n (%)     776 (73)    (68)    1347 (78)    345 (13)      Synthetic garf    6 (1)    8 (1)    220 (14)	Men, <i>n</i> (%)	285 (59)	451 (61)	1367 (63)	20 001 (62)
Caucasians    406 (84)    636 (85)    1544 (75)    217 (21)      Asians    17 (4)    22 (3)    133 (6)    3084 (10)      Indignous'    39 (8)    46 (6)    22 S (1)    3584 (12)      Others    22 (5)    37 (5)    170 (8)    3064 (11)      BMI (ategories (%)    26.7 ± 6.7    26.8 ± 6.1    27.5 ± 7.0    28.5 ± 7.1      BMI (ategories (%)    173 (28)    27.6 (40)    704 (21)    0.97 (72) (31)    0.97 (72) (31)      Overweight    148 (33)    219 (31)    0.91 (90)    1008 (32)      Obes    105 (23)    173 (25)    579 (28)    10980 (33)      Dialysia modality, n (%)    74 (13)    24 (01)    24 (01)    24 (01)      Dialysia access, n (%)    138 (19)    398 (19)    996 (30)    20 (37)      Synthetic gaft    61 (1)    8 (1)    28 (19)    395 (19)    1367 (31)      Synthetic gaft    101 (14)    29 (12)    381 (18)    424 (16)    27 (49)    36 (41)    37 (41)    26 (13)    36 (12)    36 (14)	Ethnicity, <i>n</i> (%)				
Asins    17 (4)    22 (3)    13 (6)    J041 (10)      Indigenous"    39 (8)    46 (6)    228 (1)    J384 (12)      Others    22 (5)    37 (5)    170 (8)    J364 (11)      BMI (near 250), kg/m²    26 7 ± 6.7    26 8 ± 7.10    70 (4)    100 (5)    385 (12)      IND cargories, n (%)    173 (25)    757 (9)    970 (13)    Obes    100 (6) (3)    20 (10) <td>Caucasians</td> <td>406 (84)</td> <td>636 (86)</td> <td>1634 (76)</td> <td>21 752 (67)</td>	Caucasians	406 (84)	636 (86)	1634 (76)	21 752 (67)
Indigenous <sup>4</sup> 39 (8)    46 (6)    22 (1)    3834 (12)      DM (ensar ± 5D), kg/m <sup>4</sup> 26 7.2 6.7    26.8 ± 6.1    27.5 7.0    28.5 ± 7.1      BM (ensar ± 5D), kg/m <sup>4</sup> 27 (6)    30 (4)    100 (5)    895 (3)      Normal    172 (33)    276 (40)    748 (37)    970 (2)      Normal    172 (33)    219 (31)    619 (30)    1008 (35)      Obese    105 (22)    173 (25)    579 (28)    1098 (35)      Dalysis modality, n (%)      82 (10)    2406 (75)      HD    45 (64)    640 (48)    1784 (82)    2406 (75)      Dalysis access, n (%)     398 (19)    966 (50)      CVC    320 (67)    501 (68)    134 (19)    398 (19)    466 (7)      Synthetic garli    6 (11    8 (1)    240 (1)    453 (12)    78 (1)    243 (43)    4407 (13)      Synchetic garli    6 (11    8 (1)    240 (1)    455 (3)    50 (4)    1305 (1)    253 (3)    67 (4)    1305 (7)      Databeer	Asians	17 (4)	22 (3)	133 (6)	3084 (10)
Othes    22 (5)    37 (5)    17 (8)    3601 (11)      BMI (near SD), kg/m <sup>2</sup> 267 ± 6.7    28 ± 6.1    27 5 ± 7.0    28 ± 7.1      BMI categories, r (%)           Overweight    172 (28)    276 (40)    748 (37)    9702 (31)      Overweight    148 (33)    219 (31)    619 (30)    1006 (32)      Obes    105 (32)    173 (25)    579 (28)    10980 (35)      Dalysis modulity, n(%)      24064 (75)    24064 (75)      HD    415 (86)    649 (88)    1748 (82)    24064 (75)      Dalysis modulity, n(%)      200 (30)    20 (11)    246 (31)      Dalysis acces, n(%)      388 (19)    9696 (30)      CVC    320 (67)    501 (48)    1347 (63)    1347 (63)    2510 (26)      Synthetic gaft    61 (1)    8 (1)    86 (1)    1367 (41)    264 (47) (40)    250 (27)      CVC    320 (67)    504 (42)    747 (48)    967 (40) <td< td=""><td>Indigenous<sup>a</sup></td><td>39 (8)</td><td>46 (6)</td><td>228 (11)</td><td>3834 (12)</td></td<>	Indigenous <sup>a</sup>	39 (8)	46 (6)	228 (11)	3834 (12)
BM (mean ± 5D), kg/m²    26.7    26.8 ± 6.1    27.5 ± 7.0    28.5 ± 7.1      BM (actgories, rt %)    "	Others	22 (5)	37 (5)	170 (8)	3604 (11)
BMI categories, n (%)    underweight    27 (6)    30 (4)    100 (5)    895 (5)      Normal    172 (38)    276 (40)    748 (37)    9702 (31)      Overweight    148 (33)    219 (31)    619 (30)    10061 (32)      Obese    105 (23)    173 (25)    579 (28)    10980 (35)      Dialysis modality, n (%)      24064 (75)    24064 (75)      HD    415 (86)    649 (48)    1748 (82)    24064 (75)      Dialysis acces, n (%)      388 (19)    9696 (30)      CVC    330 (67)    501 (68)    1347 (63)    657 (43)      Synthetic graft    6 (1)    8 (1)    88 (10)    682 (13)      Non-smoker    250 (43)    304 (42)    887 (42)    1467 (46)      Current smoker    28 (12)    78 (11)    288 (13)    4067 (13)      Ex-smoker    130 (21)    166 (23)    509 (24)    4229 (13)      Coronary areny disease    124 (45)    365 (49)    1161 (3)    1307 (41)      Coronary areny disease	BMI (mean $\pm$ SD), kg/m <sup>2</sup>	$26.7\pm6.7$	$26.8\pm6.1$	$27.5 \pm 7.0$	$28.5\pm7.1$
Underweight    27 (6)    30 (4)    100 (5)    985 (3)      Normal    172 (38)    276 (40)    748 (37)    9702 (31)      Overweight    148 (33)    219 (31)    619 (30)    10061 (32)      Dialysis modality, $n$ (%)          PD    69 (14)    92 (12)    381 (18)    8210 (25)      HD    415 (86)    649 (88)    1754 (82)    24064 (75)      Hom eHD    2 (0.4)    2 (0.3)    2 (0.1)    266 (08)      Dialysis acces, $n$ (%)     313 (19)    398 (19)    9696 (30)      CV C    320 (67)    501 (68)    1347 (63)    1367 (43)      Synthetic gaft    6 (1)    8 (1)    29 (1)    381 (18)    8210 (26)      Synthetic gaft    101 (14)    92 (12)    381 (18)    8210 (26)      Synthetic gaft    213 (15)    304 (42)    887 (42)    14671 (46)      Current smoker    213 (15)    314 (18)    967 (48)    1397 (49)      Constinstanoker    1213 (13)    1	BMI categories, <i>n</i> (%)				
Normal    172 (28)    276 (40)    744 (37)    9702 (31)      Obese    105 (23)    173 (25)    579 (28)    10980 (35)      Diabyis modality, n (%)          PD    69 (14)    92 (12)    381 (18)    8210 (25)      HD    415 (86)    649 (88)    1784 (62)    24064 (75)      Hom HD    2 (0.4)    2 (0.3)    2 (0.1)    266 (0.8)      Dialysis access, n (%)      398 (19)    9966 (30)      CVC    320 (67)    50 (168)    1347 (63)    13673 (43)      Synthetic graft    6 (1)    8 (1)    28 (1)    455 (1)      PO canteer    320 (67)    50 (168)    1347 (63)    4607 (13)      Sonding status, n (%)      28 (13)    467 (14)      Current smoker    25 (42)    74 (41)    28 (13)    467 (14)      Conorid ling, disease    100 (21)    166 (23)    590 (24)    429 (13)      Conorid ling, disease    124 (45)    354 (48)    1079 (63)	Underweight	27 (6)	30 (4)	100 (5)	895 (3)
Overweight    148 (33)    219 (31)    619 (30)    100 (61 (32)      Diblysis modality, n (%)          PD    69 (14)    92 (12)    381 (18)    8210 (25)      HD    415 (66)    649 (88)    1754 (62)    24064 (75)      Dialysis acces, n (%)    2 (0.1)    26 (0.8)    136 (19)    969 (610)      Dialysis acces, n (%)    18 (19)    398 (19)    9696 (30)    CVC    320 (67)    501 (68)    1347 (63)    13673 (43)      Synthetic graft    6 (1)    8 (1)    29 (1)    453 (1)    126 (7)    501 (68)    1347 (63)    1367 (43)      Synthetic graft    6 (1)    8 (1)    29 (1)    453 (1)    460 (1) (40)    1467 (140)      Carce restring issase    213 (45)    347 (48)    967 (46)    13057 (41)    260 (3)    4067 (13)      Comonstring disease    100 (21)    166 (23)    590 (24)    4229 (13)    60 (130)    771 (13)    263 (13)    416 (15)    112 255 (35)    267 (12)    388 (18)    435 (12)	Normal	172 (38)	276 (40)	748 (37)	9702 (31)
Obese    173 (25)    757 (28)    10980 (35)      PD    69 (14)    92 (12)    381 (18)    8210 (25)      HD    415 (66)    619 (88)    1784 (82)    24 (064 (75)      Home HD    2 (0.4)    2 (0.3)    2 (0.1)    266 (0.8)      Dabayisa access, n (%)          Native AVF    85 (18)    138 (19)    398 (19)    966 (30)      Synthetic graft    6 (1)    8 (1)    29 (1)    455 (1)      Synchaster    101 (14)    92 (12)    381 (18)    8210 (26)      Synchaster    205 (3)    304 (42)    887 (42)    1467 1 (46)      Current smoker    25 12 (78 (11)    268 (13)    4067 (13)      Caronstrokites, n (%)      273 (45)    374 (48)    3967 (46)    13057 (41)      Coronic lung disease    100 (21)    166 (23)    390 (24)    4229 (13)    453 (12)      Chronic lung disease    103 (21)    169 (23)    389 (18)    373 (32)    273 (42)    378 (12)    378 (12)	Overweight	148 (33)	219 (31)	619 (30)	10 061 (32)
Dialysis modality, n (%)    PD    69 (14)    92 (12)    381 (18)    8210 (25)      HD    415 (86)    649 (88)    1784 (82)    24 604 (75)      Dialysis acces, n (%)    2 (0.4)    2 (0.1)    266 (0.8)      Native AVF    85 (18)    138 (19)    398 (19)    9696 (30)      CVC    320 (67)    501 (68)    1347 (63)    13673 (43)      Synthetic graft    6 (1)    8 (1)    29 (1)    455 (1)      PD catheter    101 (14)    92 (12)    381 (18)    452 (13)      Smoking status, n (%)	Obese	105 (23)	173 (25)	579 (28)	10 980 (35)
PD    69 (14)    92 (12)    381 (18)    8210 (25)      Home HD    2 (0.4)    2 (0.3)    2 (0.1)    26 (0.8)      Dialysis acces, n (%)      2 (0.1)    26 (0.8)      Synthetic graft    6 (1)    8 (19)    398 (19)    9969 (50)      CVC    320 (67)    501 (68)    1347 (63)    136 73 (43)      Synthetic graft    6 (1)    8 (1)    29 (1)    45 (1)      PD catheter    101 (14)    92 (12)    381 (18)    8210 (26)      Smoking status, n (%)       446 (71 (46)      Current insoker    25 (12)    78 (11)    268 (13)    4067 (13)      Camobidities, n (%)        422 (13)      Consonidures, n (%)        423 (22)    413 (23)    414 (21)    453 (21)      Consonidures, n (%)       347 (48)    367 (49)    353 (12)    578 (13)    389 (18)    378 (12)      Consoniduresace    136 (21) <td>Dialysis modality, <i>n</i> (%)</td> <td></td> <td></td> <td></td> <td></td>	Dialysis modality, <i>n</i> (%)				
HD    415 (86)    649 (88)    1784 (82)    24 064 (75)      Dialysis acces, n (%)	PD	69 (14)	92 (12)	381 (18)	8210 (25)
Home HD    2 (0.4)    2 (0.5)    2 (0.1)    2 66 (0.8)      Indiysis access, n (%)	HD	415 (86)	649 (88)	1784 (82)	24064 (75)
Datayas access, n (%) Native AVF (%) Synthetic graft 6(1) (%) (1347 (63) 13673 (43) Synthetic graft 6(1) (%) (1) 29(1) (455 (14) PD catheter 101 (14) 92 (12) 381 (18) 8210 (26) Smoking status, n (%) Non-smoker 205 (43) 304 (42) 887 (42) 14671 (46) Current smoker 58 (12) 78 (11) 268 (13) 4067 (13) Ex-smoker 213 (45) 347 (48) 997 (49) 13057 (41) Comorbidities, n (%) Chronic lung disease 100 (21) 166 (23) 509 (24) 4229 (13) Coronary artery disease 100 (21) 166 (23) 399 (24) 4229 (13) Coronary artery disease 100 (21) 166 (23) 399 (24) 4229 (13) Coronary artery disease 103 (21) 169 (23) 389 (18) 3783 (12) Diabetes mellitus 15 (3) 20 (3) 86 (4) 13707 (4) Type 1 diabetes mellitus 237 (49) 354 (48) 1079 (50) 14977 (47) Cancer 51 (11) 223 (36) 335 (16) 3364 (12) Catae regulation (%) Catae regulation (%) Catae regulation explorations (%) Catae regulation explorations (%) Catae regulation explorations (%) Catae regulation explorations (%) Catae regulation exploration explorations (%) Catae regulation exploration explorations (%) Catae regulation exploration explorations (%) Catae regulation (%) State (entropy regulation (%) State (ent	Home HD	2 (0.4)	2 (0.3)	2 (0.1)	266 (0.8)
Native AVF    85 (18)    1.58 (19)    .996 (19)    .996 (20)      CVC    320 (67)    501 (68)    1.347 (63)    1.3673 (43)      Synthetic graft    6 (1)    8 (1)    29 (1)    .455 (1)      PD catheter    101 (14)    92 (12)    381 (18)    .8210 (26)      Smoking status, n (%)	Dialysis access, n (%)	05 (10)		200 (10)	
CVC $320 (67)$ $501 (88)$ $134, (63)$ $1457, (43)$ Synthetic graft $61$ $81$ $22 (12)$ $381 (18)$ $825 (1)$ PD catheter $101 (14)$ $92 (12)$ $381 (18)$ $8210 (26)$ Smoking status, $n$ (%) $22 (12)$ $381 (18)$ $887 (42)$ $14671 (46)$ Current smoker $205 (43)$ $304 (42)$ $887 (42)$ $14671 (46)$ Current smoker $213 (45)$ $347 (48)$ $967 (46)$ $13057 (41)$ Comothidities, $n (%)$ $T$ $T$ $T$ $T$ Chronic lung disease $100 (21)$ $166 (23)$ $509 (24)$ $4229 (13)$ Coronary artery disease $134 (28)$ $234 (32)$ $641 (30)$ $5979 (19)$ Cerebrovascular disease $103 (21)$ $169 (23)$ $389 (18)$ $3783 (12)$ Diabetes mellitus $15 (3)$ $20 (3)$ $86 (4)$ $1370 (4)$ Type 1 diabetes mellitus $237 (49)$ $354 (48)$ $1079 (50)$ $14977 (47)$ Cancer $51 (11)$ $223 (36)$ $673 (32)$ $6571 (21)$ Cause of kidney failure, $n (\%)$ $110 (29) (27)$ $9 (1)$ $43 (2)$ $1786 (6)$ Urban $326 (68)$ $481 (66)$ $1447 (67)$ $21399 (67)$ Cytic kidney diseas $9 (2)$ $9 (1)$ $43 (2)$ $1783 (42)$ Optimum Mark $326 (68)$ $481 (66)$ $1447 (67)$ $21399 (67)$ Cause of kidney disease $9 (2)$ $9 (1)$ $43 (23)$ $163 (23)$ Gomerulonephritis $62 (13)$ $81 (11)$ <	Native AVF	85 (18)	138 (19)	398 (19)	9696 (30)
Synthetic graft $6 (1)$ $8 (1)$ $29 (1)$ $450 (1)$ PD catheter $10 (14)$ $92 (2)$ $381 (18)$ $820 (26)$ Smoking status, $n$ (%) </td <td></td> <td>320 (67)</td> <td>501 (68)</td> <td>1347 (63)</td> <td>13673 (43)</td>		320 (67)	501 (68)	1347 (63)	13673 (43)
PD catheter101 (14)92 (12)381 (18)82 (10 (28)Smoking status, $n$ (%)Non-smoker205 (43)304 (42)887 (42)14 (67) (46)Current smoker213 (45)347 (48)967 (46)13057 (41)Comorbidities, $n$ (%) </td <td>Synthetic graft</td> <td>6(1)</td> <td>8(1)</td> <td>29 (1)</td> <td>455 (1)</td>	Synthetic graft	6(1)	8(1)	29 (1)	455 (1)
Smoking status, $n$ (%)Non-smoker205 (43)304 (42)887 (42)14671 (46)Current smoker58 (12)78 (11)268 (13)4467 (13)Ex-smoker213 (45)347 (48)967 (46)13057 (41)Comorbidities, $n$ (%)4229 (13)Coronary attery disease100 (21)166 (23)509 (24)4229 (13)Coronary attery disease134 (28)234 (32)641 (30)5579 (19)Carebrovascular disease134 (28)234 (32)641 (30)5579 (19)Carebrovascular disease133 (21)169 (23)389 (18)3783 (12)Diabets mellitus15 (3)20 (3)86 (4)1370 (4)Type 1 diabets mellitus15 (31)223 (30)335 (16)3804 (12)Late nephrologist referral150 (31)248 (34)837 (39)12323 (38)Cloner ologist referral150 (31)214 (34)837 (39)12323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%)Urban326 (68)481 (66)1447 (67)21399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Regional130 (27)233 (32)583 (23)1215 (38)Glowerulonephritis150 (22)196 (27)708 (33)10007 (31) <td< td=""><td>PD catheter</td><td>101 (14)</td><td>92 (12)</td><td>381 (18)</td><td>8210 (26)</td></td<>	PD catheter	101 (14)	92 (12)	381 (18)	8210 (26)
Non-smoker205 (4.3) $304 (4.2)$ $88 / (4.2)$ $144o/1 (46)$ Current smoker58 (12)78 (11)268 (13) $4067 (13)$ Ex-smoker213 (45) $347 (48)$ $967 (46)$ $13057 (41)$ Comorbidities, $n (\%)$ $166 (23)$ $509 (24)$ $4229 (13)$ Coronary artery disease124 (45) $355 (49)$ $1161 (54)$ $11265 (55)$ Peripheral vacular disease $103 (21)$ $169 (23)$ $389 (18)$ $3783 (12)$ Diabetes mellitus15 (3) $20 (3)$ $86 (4)$ $1370 (4)$ Type 1 diabetes mellitus $237 (49)$ $354 (48)$ $1079 (50)$ $14977 (47)$ Cancer51 (11)223 (30) $355 (16)$ $3804 (12)$ Late nephrologist referral $150 (31)$ $263 (36)$ $673 (32)$ $6571 (21)$ Causer of kidney failure, $n (\%)$ $12323 (38)$ $388 (18)$ $4834 (15)$ Diabetic nephropathy $779 (37)$ $248 (34)$ $837 (39)$ $12323 (38)$ Giomerulonephritis $62 (13)$ $81 (11)$ $246 (11)$ $6168 (19)$ Hypertension nephroselerosis $94 (12)$ $270 (36)$ $651 (30)$ $7163 (22)$ Geographical location, $n (\%)$ $147 (30)$ $194 (27)$ $633 (30)$ $10007 (31)$ Mid $166 (34)$ $317 (43)$ $832 (32)$ $284 (31)$ $299 (12) (33 (32))$ State/territory at dialysis initiation, $n (\%)$ $117 (5)$ $203 (3)$ $117 (5)$ $2058 (6)$ Set, $n (\%)$ $127 (33)$ $196 (27)$ $708 (33)$ <	Smoking status, <i>n</i> (%)	205 (12)	204 (42)	007 (42)	
Lurrent smoker $58 (12)$ $78 (11)$ $268 (13)$ $400/ (13)$ Ex-smoker $213 (45)$ $347 (48)$ $967 (46)$ $13 057 (41)$ Chronic lung disease $100 (21)$ $166 (23)$ $509 (24)$ $4229 (13)$ Coronary attery disease $214 (45)$ $365 (49)$ $1161 (54)$ $112 65 (55)$ Peripheral vascular disease $134 (28)$ $224 (32)$ $641 (30)$ $5579 (19)$ Cerebrovascular disease $103 (21)$ $169 (23)$ $389 (18)$ $3783 (12)$ Diabetes mellitus $15 (3)$ $20 (3)$ $86 (4)$ $1370 (4)$ Type 1 diabetes mellitus $237 (49)$ $354 (48)$ $1079 (50)$ $14 977 (47)$ Cancer $51 (11)$ $223 (30)$ $335 (16)$ $3804 (12)$ Late endphrologist referral $150 (31)$ $263 (36)$ $673 (32)$ $6571 (21)$ Cause of kidney failure, $n (%)$ $U$ $248 (34)$ $837 (39)$ $12 323 (8)$ Glomerulonephritis $62 (13)$ $81 (11)$ $246 (11)$ $6168 (19)$ Hypertension nephroselerosis $94 (19)$ $133 (18)$ $388 (18)$ $483 (15)$ Cystic kidney disease $9 (2)$ $9 (1)$ $43 (2)$ $1786 (6)$ Others $140 (29)$ $270 (36)$ $651 (30)$ $7163 (22)$ Geographical location, $n (\%)$ $U$ $U$ $463 (21)$ $786 (6)$ Urban $326 (68)$ $481 (66)$ $1447 (67)$ $21 399 (67)$ Remote $27 (6)$ $20 (3)$ $117 (5)$ $2058 (6)$ SES, $n (\%)$ $1$	Non-smoker	205 (43)	304 (42)	887 (42)	14 671 (46)
Lb: Simoker  215 (45)  347 (48)  967 (46)  1305 (41)    Comorbidities, n (%)	Current smoker	58 (12)	/8 (11)	268 (13)	4067 (13)
$\begin{array}{ c c c c c } \mbox{Lonorbalitys, $h$ ($s$)} \\ \hline Chronic (\ln q) disease & 100 (21) & 166 (23) & 509 (24) & 4229 (13) \\ \hline Coronary artery disease & 214 (45) & 365 (49) & 1161 (54) & 11265 (35) \\ \hline Peripheral vascular disease & 134 (28) & 234 (32) & 641 (30) & 5979 (19) \\ \hline Cerebrovascular disease & 103 (21) & 169 (23) & 389 (18) & 3783 (12) \\ \hline Diabetes mellitus & & & & & & & & & & & & & \\ Type 1 diabetes mellitus & & 15 (3) & 20 (3) & 86 (4) & 1370 (4) \\ Type 2 diabetes mellitus & 237 (49) & 354 (48) & 1079 (50) & 14977 (47) \\ \hline Cancer & & 51 (11) & 223 (30) & 335 (16) & 3804 (12) \\ Late nephroligit referral & 150 (31) & 263 (36) & 673 (32) & 6571 (21) \\ \hline Cause of kidney failure, $n$ (%) & & & & & & & & & & & \\ \hline Diabetic nephropathy & 179 (37) & 248 (34) & 837 (39) & 12 323 (38) \\ \hline Glomerulonephritis & 62 (13) & 81 (11) & 246 (11) & 6168 (19) \\ \hline Hypertension nephrosclerosis & 94 (19) & 133 (18) & 388 (18) & 4834 (15) \\ Cystic kidney diseae & 9 (2) & 9 (1) & 43 (2) & 1786 (6) \\ Others & 140 (29) & 270 (36) & 651 (30) & 7163 (22) \\ \hline Geographical location, $n$ (%) & & & & & & & & & & & & & \\ Urban & 326 (68) & 4481 (66) & 1447 (67) & 21 399 (67) \\ Regional & 130 (27) & 233 (32) & 583 (27) & 8541 (27) \\ Remote & 27 (6) & 20 (3) & 117 (5) & 2058 (6) \\ SES, $n$ (%) & & & & & & & & & & & & & & & & \\ Low & 147 (30) & 104 (27) & 633 (30) & 10007 (31) \\ Mid & 166 (34) & 317 (43) & 832 (39) & 12 135 (38) \\ High & 166 (34) & 317 (43) & 832 (39) & 12 135 (38) \\ State/territory at dialysis initiation, $n$ (%) & & & & & & & & & & & & & & & & & & &$	Ex-smoker	213 (45)	347 (48)	967 (46)	13 057 (41)
Chronic tung disease100 (21)106 (23)309 (24)4229 (13)Coronary artery disease134 (28)234 (32)641 (30)5979 (19)Cerebrovascular disease103 (21)169 (23)389 (18)3783 (12)Diabetes mellitus15 (3)20 (3)86 (4)1370 (4)Type 1 diabetes mellitus237 (49)354 (48)1079 (50)14 977 (47)Cancer51 (11)223 (30)335 (16)3804 (12)Cancer51 (11)223 (30)335 (16)3804 (12)Cause of kidney failure, n (%)179 (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4434 (15)Cystic kidney disase9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, n (%)Urban326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2088 (6)SES, n (%)Urban166 (34)317 (43)832 (39)12 35 (38)High107 (22)166 (27)708 (33)10 007 (31)Mid166 (34)316 (42)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)Victoria121 (25)180 (24)463 (21)<	Comorbiaities, <i>n</i> (%)	100 (21)	1(( (22))	500 (24)	(12)
Coronary artery insease214 (43)360 (49)110 (34)11 265 (35)Peripheral vascular disease134 (28)234 (32)641 (30)5979 (19)Carebrovascular disease103 (21)169 (23)389 (18)3783 (12)Diabetes mellitusType 1 diabetes mellitus237 (49)354 (48)1079 (50)14 977 (47)Cancer51 (11)223 (30)335 (16)3804 (12)Late nephrologist referral(50 (31)263 (36)673 (32)6571 (21)Cause of kidney failure, n (%)Typ (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, n (%)Urban326 (68)481 (66)1447 (67)21 399 (67)Remote27 (6)20 (3)117 (5)205 (6)SES, n (%)Urban150 (22)196 (27)708 (33) (10 007 (31)Mid166 (34)317 (43)332 (39)12 135 (38)High170 (35)222 (30)680 (32)984 (21)Sets, n (%)Urban121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)New South Wales105 (22)196 (27)708 (33)10 096 (31)	Chronic lung disease	100 (21)	166 (23)	509 (24)	4229 (13)
reprint a vascular disease134 (26)234 (32)641 (30) $357,91(3)$ Cerebroxacular disease103 (21)169 (23)389 (18) $3773 (12)$ Diabetes mellitus15 (3)20 (3)86 (4)1370 (4)Type 1 diabetes mellitus237 (49)354 (48)1079 (50)14977 (47)Cancer51 (11)223 (30)335 (16)3804 (12)Late nephrologist referral150 (31)263 (36)673 (32)6571 (21)Cause of kidney failure, n (%)Cause of kidney failure, n (%)811 (11)246 (11)6168 (19)Hypertension nephroselerosis9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, n (%)U233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, n (%)U170 (35)222 (30)680 (32)9842 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High170 (35)222 (30)680 (32)9842 (31)State/territory at dialysis initiation, n (%)150 (22)166 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (24)Australian68 (14)83 (11)295 (14)3408 (11)New South Wales105 (22)196 (31)664 (24)Australian Capital Territory8 (2)2	Coronary artery disease	214 (45)	365 (49) 224 (22)	(41, (20))	11 265 (35) 5070 (10)
Created by Use of the set o	Combineral vascular disease	134 (28)	234 (32)	641 (50)	3979 (19) 3793 (12)
Type 1 diabetes melitus    15 (3)    20 (3)    86 (4)    1370 (4)      Type 2 diabetes melitus    237 (49)    354 (48)    1079 (50)    14 977 (47)      Cancer    51 (11)    223 (30)    335 (16)    3804 (12)      Late nephrologist referal    150 (31)    263 (36)    673 (32)    6571 (21)      Cause of kidney failure, n (%)     817 (11)    248 (34)    837 (39)    12 323 (38)      Glomerulonephritis    62 (13)    81 (11)    246 (11)    6168 (19)      Hypertension nephrosclerosis    94 (19)    133 (18)    388 (18)    4834 (15)      Cystic kidney disease    9 (2)    9 (1)    43 (2)    1786 (6)      Others    140 (29)    270 (36)    651 (30)    7163 (22)      Geographical location, n (%)      130 (27)    233 (32)    583 (27)    8541 (27)      Remote    27 (6)    20 (3)    117 (5)    2058 (6)    585, n (%)    121 (25)    240 (24)    463 (21)    764 (24)      Mid    166 (34)    317 (43)    832 (39)<	Dish ataa mallitua	103 (21)	169 (23)	589 (18)	5785 (12)
Type 1 diabets mellitus15 (2)20 (3)30 (4)15 (7)Type 2 diabets mellitus237 (49)354 (48)1079 (50)14 977 (47)Cancer51 (11)223 (30)335 (16)3804 (12)Late nephrologist referral150 (31)263 (36)673 (32)6571 (21)Cause of kidney failure, $n$ (%)179 (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%)Urban326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%)170 (35)222 (30)680 (32)9842 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High170 (25)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Victoria121 (25)180 (24)463 (21)7664 (24)Victoria121 (25)180 (24)463 (21)7664 (24)Victoria121 (25)180 (24)463 (21)7664 (24)Victoria121 (25)180 (24)463 (21)7664 (24)South A	Type 1 diabetes mellitus	15 (3)	20 (3)	86 (4)	1370(4)
Type 2 tabletes infinitis $20'$ (9) $54'$ (4s) $10'9'$ (30) $14'97'$ (4r)Cancer51 (11)223 (30)335 (16)3804 (12)Late nephrologist referral150 (31)263 (36) $673$ (32) $6571$ (21)Cause of kidney failure, $n$ (%) $79'$ (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%) $W$ $W$ $W$ $W$ Urban326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%) $W$ 147 (30)194 (27)633 (30)10 007 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High107 (25)120 (23)680 (32)9842 (31)State/territory at dialysis initiation, $n$ (%) $W$ $457 (49)$ $453 (21)$ New South Wales105 (22)196 (27)708 (33)10 096 (31)Queensland107 (22)188 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664	Type 2 diabetes mellitus	237(49)	20(3)	1079 (50)	1370(4) 14.977(47)
Late nephrologist referral15 (11)225 (30)35 (10)350 (12)Cause of kidney failure, $n$ (%)73 (36)673 (32)6571 (21)Diabetic nephropathy179 (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%)130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%)147 (30)194 (27)633 (30)10 007 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High105 (22)196 (27)708 (33)10 096 (31)Mud107 (22)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (21)Victoria121 (25)180 (24)463 (21)7664 (21)Victoria48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1327 (4)Tamania12 (3)19 (3)31 (1)601 (2)	Concer	51 (11)	223 (30)	335 (16)	3804(12)
Late in principal retrintList (31)List (31)List (31)List (31)List (31)List (31)Cause of kidney failure, $n$ (%)Diabetic nephropathy179 (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%) </td <td>Late nephrologist referral</td> <td>150 (31)</td> <td>263 (36)</td> <td>673 (32)</td> <td>6571 (21)</td>	Late nephrologist referral	150 (31)	263 (36)	673 (32)	6571 (21)
Calculation (n (%)Diabetic nephropathy179 (37)248 (34)837 (39)12 323 (38)Glomerulonephritis62 (13)81 (11)246 (11)6168 (19)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others9 (2)9 (1)43 (2)1786 (6)Others9 (2)9 (1)43 (2)1786 (6)Geographical location, n (%)130 (27)Urban326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, n (%)100 (27)633 (30)10 007 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High170 (35)222 (30)680 (32)9842 (31)State/territory at dialysis initiation, n (%)186 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tamania12 (3)19 (3)31 (1)601 (2)	Cause of kidney failure $n$ (%)	150 (51)	203 (30)	075 (32)	03/1 (21)
Bindex HumphanyBy (B)By (B)By (B)By (B)By (B)By (B)Glomerulonephritis $62$ (13) $81$ (11) $46$ (11) $616$ (19)Hypertension nephrosclerosis $94$ (19) $133$ (18) $388$ (18) $4834$ (15)Cystic kidney disease $9$ (2) $9$ (1) $43$ (2) $1786$ (6)Others $140$ (29) $270$ (36) $651$ (30) $7163$ (22)Geographical location, $n$ (%) $140$ (29) $270$ (36) $651$ (30) $7163$ (22)Gregoraphical location, $n$ (%) $130$ (27) $233$ (32) $583$ (27) $8541$ (27)Remote $27$ (6) $20$ (3) $117$ (5) $2058$ (6)SES, $n$ (%) $147$ (30) $194$ (27) $633$ (30) $10007$ (31)Mid $166$ (34) $317$ (43) $832$ (39) $12135$ (38)High $170$ (35) $222$ (30) $680$ (32) $9842$ (31)State/territory at dialysis initiation, $n$ (%) $196$ (27) $708$ (33) $10096$ (31)Queensland107 (22) $196$ (27) $708$ (33) $10096$ (31)Queensland107 (22) $180$ (24) $463$ (21) $7664$ (24)Australian Capital Territory $8$ (2) $27$ (4) $41$ (2) $664$ (2)South Australia $48$ (10) $58$ (8) $132$ (6) $2260$ (7)Western Australia $68$ (14) $83$ (11) $295$ (14) $3408$ (11)Northern Territory $15$ (3) $10$ (1) $58$ (3) $1237$	Diabetic nephronathy	179 (37)	248 (34)	837 (39)	12 323 (38)
Hypertension nephrosclerosis92 (19)133 (18)240 (11)0100 (12)Hypertension nephrosclerosis94 (19)133 (18)388 (18)4834 (15)Cystic kidney disease9 (2)9 (1)43 (2)1786 (6)Others140 (29)270 (36)651 (30)7163 (22)Geographical location, $n$ (%) $Urban$ 326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%) $Urban$ 166 (34)317 (43)832 (39)12 135 (38)High170 (35)222 (30)680 (32)9842 (31)State/territory at dialysis initiation, $n$ (%) $Victoria$ 121 (25)180 (24)463 (21)New South Wales105 (22)196 (27)708 (33)10 096 (31)Queensland1077 (22)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1277 (4)Northern Territory15 (3)10 (1)58 (3)1237 (4)	Glomerulonenbritis	62(13)	81 (11)	246 (11)	6168 (19)
Cystic kidney disease  9 (2)  9 (1)  43 (2)  1786 (6)    Others  140 (29)  270 (36)  651 (30)  7163 (22)    Geographical location, n (%)         Urban  326 (68)  481 (66)  1447 (67)  21 399 (67)    Regional  130 (27)  233 (32)  583 (27)  8541 (27)    Remote  27 (6)  20 (3)  117 (5)  2058 (6)    SES, n (%)         Low  147 (30)  194 (27)  633 (30)  10 007 (31)    Mid  166 (34)  317 (43)  832 (39)  12 135 (38)    High  170 (35)  222 (30)  680 (32)  9842 (31)    State/territory at dialysis initiation, n (%)        New South Wales  105 (22)  196 (27)  708 (33)  10 096 (31)    Queensland  107 (22)  168 (23)  437 (20)  634 (20)    Victoria  121 (25)  180 (24)  463 (21)  7664 (24)    Australian Capital Territory  8 (2)  27 (	Hypertension nephrosclerosis	94 (19)	133 (18)	388 (18)	4834 (15)
Other Kanney Labelet    F(E)    F(F)     F(F)    F(F)<	Cystic kidney disease	9(2)	9(1)	43 (2)	1786 (6)
Geographical location, $n$ (%) $130$ (27) $233$ (32) $583$ (27) $8541$ (27)Regional130 (27)233 (32) $583$ (27) $8541$ (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%) $147$ (30)194 (27)633 (30)10 007 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High170 (35)222 (30)680 (32)9842 (31)State/territory at dialysis initiation, $n$ (%) $New$ South Wales105 (22)196 (27)708 (33)10 096 (31)Queensland107 (22)168 (23)437 (20)6344 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory $8$ (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	Others	140(29)	270 (36)	651 (30)	7163 (22)
Urban326 (68)481 (66)1447 (67)21 399 (67)Regional130 (27)233 (32)583 (27)8541 (27)Remote27 (6)20 (3)117 (5)2058 (6)SES, $n$ (%) </td <td>Geographical location, <math>n</math> (%)</td> <td>110 (29)</td> <td>270 (30)</td> <td>001 (00)</td> <td>7105 (22)</td>	Geographical location, $n$ (%)	110 (29)	270 (30)	001 (00)	7105 (22)
Regional    130 (27)    233 (32)    583 (27)    8541 (27)      Remote    27 (6)    20 (3)    117 (5)    2058 (6)      SES, n (%)      147 (30)    194 (27)    633 (30)    10007 (31)      Mid    166 (34)    317 (43)    832 (39)    12135 (38)      High    170 (35)    222 (30)    680 (32)    9842 (31)      State/territory at dialysis initiation, n (%)      New South Wales    105 (22)    196 (27)    708 (33)    10096 (31)      Queensland    107 (22)    168 (23)    437 (20)    6344 (20)    Victoria    121 (25)    180 (24)    463 (21)    7664 (24)      Australian Capital Territory    8 (2)    27 (4)    41 (2)    664 (2)    South Australia    68 (14)    83 (11)    295 (14)    3408 (11)      Northern Territory    15 (3)    10 (1)    58 (3)    1237 (4)      Tasmania    12 (3)    19 (3)    31 (1)    601 (2)	Urban	326 (68)	481 (66)	1447 (67)	21,399 (67)
Remote  27 (6)  20 (3)  117 (5)  2058 (6)    SES, n (%)	Regional	130 (27)	233 (32)	583 (27)	8541 (27)
SES, n (%)  147 (30)  194 (27)  633 (30)  10 007 (31)    Mid  166 (34)  317 (43)  832 (39)  12 135 (38)    High  170 (35)  222 (30)  680 (32)  9842 (31)    State/territory at dialysis initiation, n (%)  New South Wales  105 (22)  196 (27)  708 (33)  10 096 (31)    Queensland  107 (22)  168 (23)  437 (20)  6344 (20)    Victoria  121 (25)  180 (24)  463 (21)  7664 (24)    Australian Capital Territory  8 (2)  27 (4)  41 (2)  664 (2)    South Australia  48 (10)  58 (8)  132 (6)  2260 (7)    Western Australia  68 (14)  83 (11)  295 (14)  3408 (11)    Northern Territory  15 (3)  10 (1)  58 (3)  1237 (4)    Tasmania  12 (3)  19 (3)  31 (1)  601 (2)	Remote	27 (6)	20 (3)	117 (5)	2058 (6)
Low147 (30)194 (27)633 (30)10 007 (31)Mid166 (34)317 (43)832 (39)12 135 (38)High170 (35)222 (30)680 (32)9842 (31)State/territory at dialysis initiation, n (%)New South Wales105 (22)196 (27)708 (33)10 096 (31)Queensland107 (22)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	SES, $n$ (%)				
Mid    166 (34)    317 (43)    832 (39)    12 135 (38)      High    170 (35)    222 (30)    680 (32)    9842 (31)      State/territory at dialysis initiation, n (%)          New South Wales    105 (22)    196 (27)    708 (33)    10 096 (31)      Queensland    107 (22)    168 (23)    437 (20)    6344 (20)      Victoria    121 (25)    180 (24)    463 (21)    7664 (24)      Australian Capital Territory    8 (2)    27 (4)    41 (2)    664 (2)      South Australia    48 (10)    58 (8)    132 (6)    2260 (7)      Western Australia    68 (14)    83 (11)    295 (14)    3408 (11)      Northern Territory    15 (3)    10 (1)    58 (3)    1237 (4)      Tasmania    12 (3)    19 (3)    31 (1)    601 (2)	Low	147 (30)	194 (27)	633 (30)	10007(31)
High  170 (35)  222 (30)  680 (32)  9842 (31)    State/territory at dialysis initiation, n (%)         New South Wales  105 (22)  196 (27)  708 (33)  10 096 (31)    Queensland  107 (22)  168 (23)  437 (20)  6344 (20)    Victoria  121 (25)  180 (24)  463 (21)  7664 (24)    Australian Capital Territory  8 (2)  27 (4)  41 (2)  664 (2)    South Australia  48 (10)  58 (8)  132 (6)  2260 (7)    Western Australia  68 (14)  83 (11)  295 (14)  3408 (11)    Northern Territory  15 (3)  10 (1)  58 (3)  1237 (4)    Tasmania  12 (3)  19 (3)  31 (1)  601 (2)	Mid	166 (34)	317 (43)	832 (39)	12 135 (38)
State/territory at dialysis initiation, n (%)  New South Wales  105 (22)  196 (27)  708 (33)  10 096 (31)    Queensland  107 (22)  168 (23)  437 (20)  6344 (20)    Victoria  121 (25)  180 (24)  463 (21)  7664 (24)    Australian Capital Territory  8 (2)  27 (4)  41 (2)  664 (2)    South Australia  48 (10)  58 (8)  132 (6)  2260 (7)    Western Australia  68 (14)  83 (11)  295 (14)  3408 (11)    Northern Territory  15 (3)  10 (1)  58 (3)  1237 (4)    Tasmania  12 (3)  19 (3)  31 (1)  601 (2)	High	170 (35)	222 (30)	680 (32)	9842 (31)
New South Wales105 (22)196 (27)708 (33)10 096 (31)Queensland107 (22)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	State/territory at dialysis initiation, <i>n</i> (%)				
Queensland107 (22)168 (23)437 (20)6344 (20)Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	New South Wales	105 (22)	196 (27)	708 (33)	10096(31)
Victoria121 (25)180 (24)463 (21)7664 (24)Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	Queensland	107 (22)	168 (23)	437 (20)	6344 (20)
Australian Capital Territory8 (2)27 (4)41 (2)664 (2)South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	Victoria	121 (25)	180 (24)	463 (21)	7664 (24)
South Australia48 (10)58 (8)132 (6)2260 (7)Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	Australian Capital Territory	8 (2)	27 (4)	41 (2)	664 (2)
Western Australia68 (14)83 (11)295 (14)3408 (11)Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	South Australia	48 (10)	58 (8)	132 (6)	2260 (7)
Northern Territory15 (3)10 (1)58 (3)1237 (4)Tasmania12 (3)19 (3)31 (1)601 (2)	Western Australia	68 (14)	83 (11)	295 (14)	3408 (11)
Tasmania 12 (3) 19 (3) 31 (1) 601 (2)	Northern Territory	15 (3)	10 (1)	58 (3)	1237 (4)
	Tasmania	12 (3)	19 (3)	31 (1)	601 (2)

Continued

#### Table 1. Continued

	Early death from psychosocial withdrawal	Early death from medical withdrawal	Early death from non-withdrawal causes	Overall
Era, <i>n</i> (%)				
2005-09	185 (38)	288 (39)	889 (41)	10769 (33)
2010-13	149 (31)	220 (30)	599 (28)	8764 (27)
2014-18	150 (31)	233 (31)	677 (31)	12 741 (40)
Pre-emptive transplant, <i>n</i> (%)	1 (0.2)	0 (0)	9 (0.4)	199 (0.6)
Centre-level characteristics				
Number of centres	63	72	75	97
Transplant centre, <i>n</i> (%)	16 (28)	16 (24)	16 (24)	18 (21)
Centre size, median (IQR)				
Incidence dialysis patient/year	28 (11–51)	22 (9-46)	22 (8-45)	13 (2-40)
Incidence PD patient/year	6 (1-14)	5 (0-12)	5 (0-12)	2 (0-10)
Incidence HD patient/year	21 (10–38)	17 (6-36)	17 (6–36)	12 (2-31)
State/territory at dialysis initiation, n (%)				
New South Wales	20 (32)	24 (33)	26 (35)	32 (33)
Queensland	17 (27)	19 (26)	21 (28)	29 (30)
Victoria	13 (21)	15 (21)	15 (20)	21 (22)
Australian Capital Territory	1 (2)	2 (3)	1 (1)	2 (2)
South Australia	4 (6)	4 (6)	4 (5)	5 (5)
Western Australia	4 (6)	4 (6)	4 (5)	4 (4)
Northern Territory	2 (3)	2 (3)	2 (3)	2 (2)
Tasmania	2 (3)	2 (3)	2 (3)	2 (2)

<sup>a</sup>Indigenous—Aboriginal and Torres Strait Islander.

withdrawal-related mortality reduced from 5.3 deaths/100 person-years in 2006 to 3.1 deaths/100 person-years in 2018 ( $\tau = -0.59$ , P = 0.06), attributed to reduction of both psychosocial and medical withdrawals (Figure 2B). Figure 2C shows the annual proportions of cause-specific early mortality in Australia between 2005 and 2017, and Supplementary data, Figure S1 shows the mortality rates of early dialysis withdrawals stratified by months after dialysis initiation.

# Risk factors associated with death attributed to dialysis withdrawal

The common risk factors associated with increased risk of early mortality attributed to psychosocial and medical withdrawals were older age, dialysis access via CVC, late referral and the presence of cerebrovascular disease. The common risk factors associated with decreased risk were obesity and Asian ethnicity. Underweight and high SES were associated with increased risk for early psychosocial withdrawal only. Presence of peripheral vascular disease, chronic lung disease and cancer at time of dialysis initiation were associated with increased risk for early medical withdrawal only (Figure 3 and Supplementary data, Table S1).

For every decade increment of age, the adjusted SHRs were 1.65 (95% confidence interval 1.50–1.82) for early psychosocial withdrawal and 1.51 (1.40–1.62) for early medical withdrawal. For Asian patients, the adjusted SHRs were 0.34 (0.21–0.56) for early psychosocial withdrawal and 0.36 (0.24–0.56) for early medical withdrawal, compared with Caucasian patients.

Compared with patients with normal weight, the adjusted SHRs for underweight patients were 1.86 (1.23–2.82) for early psychosocial withdrawal and 1.19 (0.80–1.76) for early medical withdrawal. In contrast, for obese patients, the adjusted SHRs

were 0.59 (0.46–0.78) for early psychosocial withdrawal and 0.66 (0.54–0.81) for early medical withdrawal.

For late nephrologist referral, the adjusted SHRs were 1.33 (1.07–1.64) for early psychosocial withdrawal and 1.51 (1.28–1.79) for early medical withdrawal. Compared with patients who initiated dialysis via native AVF, the adjusted SHRs for patients who initiated dialysis via CVC were 2.43 (1.87–3.15) for psychosocial withdrawal and 1.99 (1.62–2.43) for medical withdrawal. No statistically significant association was observed between dialysis initiation via synthetic graft or PD catheter with early psychosocial or medical withdrawal.

The presence of vascular disease was associated with death from early withdrawal for psychosocial and medical reasons. Among patients with cerebrovascular disease, the adjusted SHRs were 1.51 (1.20–1.91) for early psychosocial withdrawal and 1.62 (1.34–1.92) for early medical withdrawal. For peripheral vascular disease, the adjusted SHRs were 1.25 (1.00–1.56) for early psychosocial withdrawal and 1.51 (1.27–1.80) for early medical withdrawal. For chronic lung disease, the adjusted SHRs were 1.25 (0.99–1.58) for early psychosocial withdrawal. The presence of cancer was associated with a decreased risk for early psychosocial withdrawal (SHR = 0.55, 0.40–0.75) but an increased risk for early medical withdrawal mortality (SHR = 2.05, 1.74–2.43).

Sex, era and geographical location were not associated with early death from psychosocial or medical withdrawal. Compared with middle SES, high SES was associated with increased risk for early psychosocial withdrawal (SHR = 1.33, 1.06-1.67), but no association was observed for low SES. Variability in the risk of early mortality from psychosocial or medical withdrawal was observed between different states and territories in Australia. The risk factors associated with early



**FIGURE 2:** (**A**) Annual proportions of early mortality attributed to dialysis withdrawal, stratified by psychosocial and medical withdrawals, in Australia between 2005 and 2017. (**B**) Annual incidence rates of early mortality attributed to dialysis withdrawal, stratified by psychosocial and medical withdrawals, in Australia between 2006 and 2018 ( $\tau = -0.33$ , P = 0.1 for early psychosocial withdrawal,  $\tau = -0.56$ , P = 0.009 for early medical withdrawal and  $\tau = -0.59$ , P = 0.006 for all-cause early withdrawal). (**C**) Annual proportion of early mortality, stratified by causes of early mortality, in Australia between 2005 and 2017.

psychosocial and medical withdrawals within the 12 months post-dialysis initiation are shown in Supplementary data, Table S1. Cox regression analyses showed similar estimates of the same risk factors. Centre-level covariates including centre size and transplant centre were not associated with death from early withdrawal.

#### Sensitivity analysis

In the sensitivity analysis restricted to incident patients on dialysis for >90 days, similar estimates were observed for age, ethnicity, underweight, dialysis access and presence of comorbid medical conditions. No association was observed between late referral and early psychosocial withdrawal. Low

		Adjusted SHR (95% CI)	p-value
Age	1		
Psychosocial reasons	юн	1.65 (1.50–1.82)	<0.001
Medical reasons	юн	1.51 (1.40–1.62)	<0.001
Race			
Psychosocial reasons			
Caucasian	<b>\$</b>	1.0	-
Asian		0.34 (0.21–0.56)	<0.001
Indigenous	+	0.78 (0.49–1.23)	0.3
Other		0.44 (0.28–0.69)	<0.001
Medical reasons			
Caucasian		1.0	-
Asian		0.36 (0.24–0.56)	<0.001
Indigenous	<u>_</u>	0.76 (0.52–1.11)	0.1
Other		0.51 (0.36–0.73)	<0.001
BMI			
Psychosocial reasons			
Underweight		1.86 (1.23–2.82)	0.003
Normal	<b>•</b>	1.0	-
Overweight	-1	0.84 (0.67–1.05)	0.1
Obese		0.59 (0.46–0.78)	<0.001
Medical reasons			
Underweight	+•1	1.19 (0.80–1.76)	0.4
Normal	<b>ቀ</b>	1.0	-
Overweight	1	0.78 (0.65–0.94)	0.008
Obese Hondrey		0.66 (0.54–0.81)	<0.001
Late nephrologist referral			0.04
Psychosocial reasons		1.33 (1.07–1.64)	0.01
Medical reasons	⊢⊖⊣	1.51 (1.28–1.79)	<0.001
Distanta second			
Dialysis access			
Psychosocial reasons		1.0	
Native arteriorvenous fistula	<b>¢</b>	1.0	-
Central venous catheter		2.43 (1.87–3.15)	< 0.001
Synthetic graft		1.69 (0.74–3.89)	0.2
Peritoneal dialysis catheter	<b>1</b> 01	1.12 (0.81–1.56)	0.5
Medical reasons		1.0	
Native arteriorvenous fistula		1.0	-
		1.99 (1.62–2.43)	< 0.001
Synthetic graft		1.15(0.56-2.35)	0.7
Peritoneal dialysis catheter	$\Gamma$	0.89 (0.68–1.18)	0.4
Comorbid medical conditions:			
Presence of peripheral vascular disease			
Psychosocial roscons		1 25 (1 00_1 56)	0.05
Modical reasons		1.51 (1.27_1.80)	<0.00
Medical reasons		1.51 (1.27=1.00)	<b>NO.001</b>
Presence of cerebrovascular disease			
Psychosocial reasons		1 51 (1 20-1 91)	<0.001
Medical reasons		1 62 (1 34–1 96)	<0.001
		1.02 (1.07 - 1.00)	-0.001
Presence of malignancy			
Psychosocial reasons		0.55 (0.40-0.75)	< 0.001
Medical reasons		2.05 (1.74–2.43)	< 0.001
0.1	1 1	0	

FIGURE 3: Competing risk analyses of factors associated with early mortality attributed to dialysis withdrawal for psychosocial and medical reasons.

SES was an additional risk factor for early psychosocial withdrawal (SHR = 1.39, 1.06-1.81) (Supplementary data, Table S2).

# DISCUSSION

In this observational cohort study of incident dialysis patients in Australia, one in three deaths within the first 12 months postdialysis initiation was attributed to early dialysis withdrawal, and the proportion remained unchanged over the last two decades. There were several common risk factors associated with both psychosocial and medical withdrawals including older age, Caucasian ethnicity and presence of prevalent comorbidities. These findings suggest that early identification and education relating to the risks and benefits of dialysis treatment may allow for a more informed shared decision-making process.

Our study showed early withdrawal had become the most common cause of early death after dialysis initiation in Australia, surpassing cardiovascular mortality in recent years, despite a reduction in the incidence rates of early dialysis withdrawal that was likely related to the advances in medical interventions and management strategies and the increased incidence of patients on a conservative, non-dialysis pathway [20, 21]. For patients who withdrew from dialysis, medical withdrawal consistently outnumbered psychosocial withdrawal annually. A Canadian study showed almost two in three patients with kidney failure regretted their decision to commence dialysis [22]. Although responses to questionnaires may not accurately reflect real-life decisions, the high proportion of early dialysis withdrawal highlighted in our study supports the likelihood of patients' preference for prioritizing a better quality of life (QoL) over survival. Providing adequate information forms an important part of a legally valid informed consent to dialysis [23]. Tailoring resource allocation to facilitate the transition from survival-oriented to patient-focused decision-making process and to promote the option of a conservative, nondialysis pathway in selected patient groups may minimize early withdrawal and unnecessary morbidity related to dialysis treatment [8, 10].

Contrary to other studies, our study has shown that the proportion of patients who had experienced early dialysis withdrawal has remained unchanged over the last two decades [4-7, 24]. As our study focused on early mortality within 12 months post-dialysis initiation, our primary outcome might include patients on palliative dialysis for which early withdrawal was an expected outcome [25]. It is noteworthy that ANZDATA registry reporting was revised in October 2003, with reclassification of withdrawal-related deaths [14, 17]. Hence, the temporal increase in dialysis withdrawal observed in previous ANZDATA studies may be related to misclassification bias [14, 24]. Similarly, the definition of death from dialysis withdrawal had been revised several times in the USRDS [26]. When interpreting and comparing temporal and geographical variations in withdrawal-related mortality, it is important to recognize the differences in definition of dialysis withdrawal.

With advances in dialysis technology and treatments of lifethreatening conditions, a greater number of older, frailer patients with kidney failure are being considered for dialysis [27]. However, dialysis initiation is known to be associated with significant decline in functional status [28]. In our study, older age, underweight and the presence of prevalent comorbidities were associated with increased risks for early withdrawals and were likely surrogate markers for frailty, although this domain of health is not collected by the ANZDATA registry [28–32]. Dialysis via CVC and late referral are known to be associated with significant disease and symptom burdens, which may result in higher prevalence of frailty [33–36]. Frailty is a geriatric syndrome that is closely associated with comorbidity and disability but also encompasses physiological decline. It is expected that frail patients are more likely to withdraw from dialysis due to poor health-related QoL and cognitive impairment [37-39]. Many studies are currently evaluating the best-fit frailty assessment tool for patients with kidney failure [27]. Incorporating frailty assessment into the decision-making process and treatment planning can potentially reduce the increasing burden of early dialysis withdrawal.

In our study, the risk of early medical withdrawals doubled in patients with prior cancer, compared with those without; however, the risk halved for early psychosocial withdrawals. The reason for this observation is unclear but may be related to the progressive nature of cancer in combination with delayed diagnosis and limited cancer treatment options in patients with kidney failure [40, 41]. Withdrawal of treatment in patients with prior cancer might consist of both dialysis withdrawal and withdrawal/withholding of anticancer therapy, and therefore was more likely to be considered as medical withdrawal instead of psychosocial withdrawal.

Caucasians have been reported to have a greater risk of dialysis withdrawal attributed to social supports and cultural acceptance of treatment withdrawal [24, 42]. Although our study showed similar findings, it is difficult to ascertain the correlation due to the high proportion (70%) of Caucasian dialysis patients in Australia, which was also observed in other dialysis withdrawal studies [6, 13, 24]. In many non-Western countries, dialysis initiation and withdrawal may not be based on patients' preferences, due to systemic differences in dialysis resources, palliative care access and ethico-legal regulations [43, 44]. Studies collating non-Caucasian dialysis patients in Western countries or those in non-Western countries where dialysis withdrawal is legally permitted may provide more insights into racial, religious and cultural differences in the acceptance of dialysis withdrawal.

A non-linear association between SES and early psychosocial withdrawal was observed in this study. This might reflect dissimilarities in health literacy, healthcare access and psychosocial supports between patients from different socioeconomic backgrounds. Previous studies have shown that patients with high SES were more likely to access palliative care and stay home as the place of death, suggesting a predominant emphasis on autonomy and QoL [45, 46]. In contrast, patients with low SES may lack access to community support, financial assistance and transportation to sustain long-term dialysis [47, 48]. More detailed studies focusing on specific socioeconomic determinants, including financial position, QoL and palliative care acceptance, may facilitate a greater understanding of the non-linear association between SES and early psychosocial withdrawal.

There are several limitations inherent with registry data. First, the ANZDATA registry does not collect information on patients who opt for a conservative pathway without ever initiating dialysis. Therefore, selection bias might take place. In addition, there may be ascertainment bias from underreporting of patients maintained on dialysis for <90 days, due to overlap between acute kidney injury and chronic kidney disease. Secondly, deaths from dialysis withdrawal were reported to the ANZDATA registry by the treating centres, and the registry does not verify the accuracy of these causes. Hence, misclassification bias of the cause of death is possible. Lastly, there are unmeasured and residual confounders that are likely to be dissimilar between patients who experienced death from withdrawal and those with other causes of death. Details on psychosocial factors, functional status, cognitive impairment, severity of comorbidities and mental health conditions were not collected by the ANZDATA registry. Furthermore, state-level and centre-level systemic differences, including the availability of kidney supportive care or palliative care and changes in dialysis access policies, were also not collected by the ANZDATA registry to provide a better understanding of the circumstances associated with early dialysis withdrawal.

In conclusion, early dialysis withdrawal accounted for >30% of early deaths with minimal temporal variation in the last two decades. Many of the risk factors were common between early psychosocial and medical withdrawals and may be related to surrogate measures of frailty. Detailed discussion outlining the medical and psychosocial risks and benefits of dialysis and non-dialysis pathways for high-risk patients approaching kidney failure may better inform the shared decision-making process, empower patient-focused treatment choices and facilitate informed consent and advanced care planning.

#### SUPPLEMENTARY DATA

Supplementary data are available at ndt online.

#### ACKNOWLEDGEMENTS

The authors thank the entire Australian and New Zealand Nephrology community (physicians, surgeons, database managers, nurses, renal operators and patients), which provides information to and maintains the ANZDATA registry database, for their substantial contributions. The data reported here have been supplied by the ANZDATA registry. The interpretation and reporting of these data are the responsibility of the authors and should not be seen as an official policy or interpretation of the ANZDATA registry. The authors received no financial support for the research, authorship and/ or publication of this article.

#### FUNDING

None.

#### **AUTHORS' CONTRIBUTIONS**

All authors have contributed to this manuscript and approve of this submission. J.H.C.C. and W.H.L. participated in the design and analysis of this study. All authors participated in the interpretation of data and drafting/revising the paper. The results presented in this article have not been published previously in whole or part, except in abstract form.

### CONFLICT OF INTEREST STATEMENT

D.W.J. received consultancy fees, speaker's honoraria and research grants from Baxter Healthcare and Fresenius Medical Care, travel sponsorship from Amgen, consultancy fees from Astra Zeneca and AWAK, research grants from National Health and Medical Research Council of Australia, speaker's honoraria from Ono and consultancy fees from Bayer outside the submitted work. R.W. received speaker's honoraria and research grants from Baxter Healthcare outside the submitted work. N.B. received consultancy fees from AstraZeneca and Baxter Healthcare and travel grants from Roche Pharmaceuticals and Amgen outside the submitted work. C.H. received research grants from Baxter Healthcare, Fresenius Medical Care and Shire paid to her institution and trial leadership fees from Janssen, GlaxoSmithKline and Otsuka paid to her institution. W.H.L. received research grants from Novartis and speaker's honoraria from Alexion outside the submitted work.

#### REFERENCES

- ANZDATA Registry. 21st Report, Chapter 7: Deaths. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, Australia: ANZDATA Registry, 1998
- ANZDATA Registry. 41st Report, Chapter 3: Mortality in End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, Australia: ANZDATA Registry, 2018
- Khou V, De La MN, Morton RL et al. Cause of death for people with endstage kidney disease withdrawing from treatment in Australia and New Zealand. Nephrol Dial Transplant 2020; doi: 10.1093/ndt/gfaa105
- United States Renal Data System. 1994 USRDS Annual Data Report Chapter 7: Causes of Death. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1994
- United States Renal Data System. 2018 USRDS Annual Data Report Chapter 5: Mortality. End-Stage Renal Disease (ESRD) in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2019
- Ellwood AD, Jassal SV, Suri RS *et al.* Early dialysis initiation and rates and timing of withdrawal from dialysis in Canada. *Clin J Am Soc Nephrol* 2013; 8: 265–270
- UK Renal Registry. UK Renal Registry 21st Annual Report data to 31/12/ 2017. Bristol: UK Renal Registry, 2019
- Jassal SV, Larkina M, Jager KJ *et al.* International variation in dialysis discontinuation in patients with advanced kidney disease. *CMAJ* 2020; 192: E995–E1002
- Wen Y, Jiang C, Koncicki HM *et al.* Trends and racial disparities of palliative care use among hospitalized patients with ESKD on dialysis. *J Am Soc Nephrol* 2019; 30: 1687–1696
- Robinson BM, Zhang J, Morgenstern H et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int* 2014; 85: 158–165
- Bradbury BD, Fissell RB, Albert JM et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007; 2: 89–99
- Foley RN. Epidemiology and risk factors for early mortality after dialysis initiation. Semin Nephrol 2017; 37: 114–119
- Wetmore JB, Roetker NS, Gilbertson DT *et al.* Early withdrawal and nonwithdrawal death in the months following hemodialysis initiation: a retrospective cohort analysis. *Hemodial Int* 2019; 23: 261–272
- Chan HW, Clayton PA, McDonald SP et al. Risk factors for dialysis withdrawal: an analysis of the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, 1999-2008. Clin J Am Soc Nephrol 2012; 7:775–781
- von Elm E, Altman DG, Egger M et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577
- Australian Bureau of Statistics. Socio-Economic Indexes for Areas. https:// www.abs.gov.au/websitedbs/censushome.nsf/home/seifa (27 March 2018, date last accessed).
- ANZDATA Registry. AUS. & N.Z. Dialysis and Transplant Survey. https:// www.anzdata.org.au/wp-content/uploads/2019/03/ ANZDATADialysisAndTransplantSurvey2018.pdf (25 March 2021, date last accessed)
- National Cancer Institute. Joinpoint Trend Analysis Software. Bethesda, MD: National Cancer Institute (21 April 2021, date last accessed)

- Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509
- Shah S, Leonard AC, Meganathan K *et al.* Temporal trends in incident mortality in dialysis patients: focus on sex and racial disparities. *Am J Nephrol* 2019; 49: 241–253
- De Meyer V, Abramowicz D, De Meester J *et al.* Variability in the incidence of renal replacement therapy over time in Western industrialized countries: a retrospective registry analysis. *PLoS One* 2020; 15: e0235004
- Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2010; 5: 195–204
- Brennan F, Stewart C, Burgess H *et al.* Time to improve informed consent for dialysis: an international perspective. *Clin J Am Soc Nephrol* 2017; 12: 1001–1009
- Chan S, Marshall MR, Ellis RJ et al. Haemodialysis withdrawal in Australia and New Zealand: a binational registry study. Nephrol Dial Transplant 2020; 35: 669–676
- Tentori F, Hunt A, Nissenson AR. Palliative dialysis: addressing the need for alternative dialysis delivery modes. *Semin Dial* 2019; 32: 391–395
- Murphy E, Germain MJ, Cairns H et al. International variation in classification of dialysis withdrawal: a systematic review. Nephrol Dial Transplant 2014; 29: 625–635
- van Loon IN, Goto NA, Boereboom FTJ et al. Frailty screening tools for elderly patients incident to dialysis. Clin J Am Soc Nephrol 2017; 12: 1480–1488
- Kurella Tamura M, Covinsky KE, Chertow GM *et al.* Functional status of elderly adults before and after initiation of dialysis. *N Engl J Med* 2009; 361: 1539–1547
- Iyasere O, Brown EA. Mortality in the elderly on dialysis: is this the right debate? Clin J Am Soc Nephrol 2015; 10: 920–922
- Wachterman MW, O'Hare AM, Rahman OK et al. One-year mortality after dialysis initiation among older adults. JAMA Intern Med 2019; 179: 987–990
- Okuyama M, Takeuchi H, Uchida HA et al. Peripheral artery disease is associated with frailty in chronic hemodialysis patients. Vascular 2018; 26: 425–431
- Liu T, Liang KV, Rosenbaum A *et al.* Peripheral vascular disease severity impacts health outcomes and health-related quality of life in maintenance hemodialysis patients in the HEMO Study. *Nephrol Dial Transplant* 2012; 27: 2929–2936
- Lomonte C, Basile C, Mitra S et al. Should a fistula first policy be revisited in elderly haemodialysis patients? Nephrol Dial Transplant 2019; 34: 1636–1643
- Lok CE, Foley R. Vascular access morbidity and mortality: trends of the last decade. *Clin J Am Soc Nephrol* 2013; 8: 1213–1219

- 35. Kazmi WH, Obrador GT, Khan SS *et al.* Late nephrology referral and mortality among patients with end-stage renal disease: a propensity score analysis. *Nephrol Dial Transplant* 2004; 19: 1808–1814
- 36. Smart NA, Dieberg G, Ladhani M et al. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. *Cochrane Database Syst Rev* 2014; (6): CD007333
- Nixon AC, Bampouras TM, Pendleton N *et al*. Frailty is independently associated with worse health-related quality of life in chronic kidney disease: a secondary analysis of the Frailty Assessment in Chronic Kidney Disease study. *Clin Kidney J* 2020; 13: 85–94
- Sy J, Johansen KL. The impact of frailty on outcomes in dialysis. Curr Opin Nephrol Hypertens 2017; 26: 537–542
- McAdams-DeMarco MA, Tan J, Salter ML et al. Frailty and cognitive function in incident hemodialysis patients. Clin J Am Soc Nephrol 2015; 10: 2181–2189
- Sprangers B, Van der Veen A, Hamaker ME *et al.* Initiation and termination of dialysis in older patients with advanced cancer: providing guidance in a complicated situation. *Lancet Healthy Longev* 2021; 2: E42–E52
- Wong G, Hayward JS, McArthur E et al. Patterns and predictors of screening for breast and cervical cancer in women with CKD. Clin J Am Soc Nephrol 2017; 12: 95–104
- Foley RN, Sexton DJ, Drawz P et al. Race, ethnicity, and end-of-life care in dialysis patients in the United States. J Am Soc Nephrol 2018; 29: 2387–2399
- Hyodo T, Fukagawa M, Hirawa N et al. Present status of renal replacement therapy in Asian countries as of 2016: Cambodia, Laos, Mongolia, Bhutan, and Indonesia. *Ren Replace Ther* 2019; 5: 12
- Lai CF, Tsai HB, Hsu SH et al. Withdrawal from long-term hemodialysis in patients with end-stage renal disease in Taiwan. J Formos Med Assoc 2013; 112: 589–599
- Lewis JM, DiGiacomo M, Currow DC *et al.* Dying in the margins: understanding palliative care and socioeconomic deprivation in the developed world. *J Pain Symptom Manage* 2011; 42: 105–118
- 46. Davies JM, Maddocks M, Chua KC et al. Socioeconomic position and use of hospital-based care towards the end of life: a mediation analysis using the English Longitudinal Study of Ageing. Lancet Public Health 2021; 6: e155–e163
- Qazi HA, Chen H, Zhu M. Factors influencing dialysis withdrawal: a scoping review. *BMC Nephrol* 2018; 19: 96
- Fissell RB, Bragg-Gresham JL, Lopes AA et al. Factors associated with "do not resuscitate" orders and rates of withdrawal from hemodialysis in the international DOPPS. Kidney Int 2005; 68: 1282–1288

Received: 11.4.2021; Editorial decision: 10.6.2021